Initial plasma HIV-1 RNA levels and progression to AIDS in women and men.

BACKGROUND It is unclear whether there are differences between men and women with human immunodeficiency virus type 1 (HIV-1) infection in the plasma level of viral RNA (the viral load). In men, the initial viral load after seroconversion predicts the likelihood of progression to the acquired immunodeficiency syndrome (AIDS), but the relation between the two has not been assessed in women. Currently, the guidelines for initiating antiretroviral therapy are applied uniformly to women and men. METHODS From 1988 through 1998, the viral load and the CD4+ lymphocyte count were measured approximately every six months in 156 male and 46 female injection-drug users who were followed prospectively after HIV-1 seroconversion. RESULTS The median initial viral load was 50,766 copies of HIV-1 RNA per milliliter in the men but only 15,103 copies per milliliter in the women (P<0.001). The median initial CD4+ count did not differ significantly according to sex (659 and 672 cells per cubic millimeter, respectively). HIV-1 infection progressed to AIDS in 29 men and 15 women, and the risk of progression did not differ significantly according to sex. For each increase of 1 log in the viral load (on a base 10 scale), the hazard ratio for progression to AIDS was 1.55 (95 percent confidence interval, 0.97 to 2.47) among the men and 1.43 (95 percent confidence interval, 0.76 to 2.69) among the women. The median initial viral load was 77,822 HIV-1 RNA copies per milliliter in the men in whom AIDS developed and 40,634 copies per milliliter in the men in whom it did not; the corresponding values in the women were 17,149 and 12,043 copies per milliliter. Given the recommendation that treatment should be initiated when the viral load reaches 20,000 copies per milliliter, 74 percent of the men but only 37 percent of the women in our study would have been eligible for therapy at the first visit after seroconversion (P<0.001). CONCLUSIONS Although the initial level of HIV-1 RNA was lower in women than in men, the rates of progression to AIDS were similar. Treatment guidelines that are based on the viral load, rather than the CD4+ lymphocyte count, will lead to differences in eligibility for antiretroviral treatment according to sex.

[1]  A Munoz,et al.  The Alive Study: A Longitudinal Study of HIV-1 Infection in Intravenous Drug Users: Description of Methods , 1991, NIDA research monograph.

[2]  Hiv Survival,et al.  Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis , 2000, The Lancet.

[3]  M. Salimans,et al.  Rapid and simple method for purification of nucleic acids , 1990, Journal of clinical microbiology.

[4]  Richard D Moore,et al.  Lack of sex difference in CD4 to HIV-1 RNA viral load ratio , 1999, The Lancet.

[5]  J. Margolick,et al.  Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. , 1999, The Journal of infectious diseases.

[6]  T. Louis,et al.  Survival and disease progression according to gender of patients with HIV infection. The Terry Beirn Community Programs for Clinical Research on AIDS. , 1994, JAMA.

[7]  R. Hoffman,et al.  Simple and rapid measurement of human T lymphocytes and their subclasses in peripheral blood. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Roel A. Coutinho,et al.  Time from HIV-1 seroconversion to Aids and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis: collaborative Group on Aids incubation and HIV survival including the CASCADE EU concerted action , 2000 .

[9]  R H Lyles,et al.  Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. , 2000, The Journal of infectious diseases.

[10]  J. D. Malone,et al.  Human immunodeficiency virus RNA levels in US adults: a comparison based upon race and ethnicity. , 1997, The Journal of infectious diseases.

[11]  S. Hammer,et al.  The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. , 1996, The New England journal of medicine.

[12]  D. van Strijp,et al.  The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? , 1994, Virology.

[13]  J. Mellors,et al.  Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion , 1995, Annals of Internal Medicine.

[14]  L A Kalish,et al.  The relative value of CD4 cell count and quantitative HIV-1 RNA in predicting survival in HIV-1-infected women: results of the women's interagency HIV study. , 1999, AIDS.

[15]  R. Hogg,et al.  Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after seroconversion: a predictor of long-term mortality in HIV infection. , 1997, Journal of Infectious Diseases.

[16]  Rainer Weber,et al.  Sex differences in HIV-1 viral load and progression to AIDS , 1999, The Lancet.

[17]  P. Kvale,et al.  Gender is not a factor in serum human immunodeficiency virus type 1 RNA levels in patients with viremia , 1996, Journal of clinical microbiology.

[18]  D. Burke,et al.  Serum levels of virus burden in early-stage human immunodeficiency virus type 1 disease in women. , 1997, The Journal of infectious diseases.

[19]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[20]  J. Margolick,et al.  Association of race and gender with HIV-1 RNA levels and immunologic progression. , 2000 .

[21]  J J Goedert,et al.  Natural history of HIV-1 cell-free viremia. , 1995, JAMA.

[22]  P Pezzotti,et al.  Longitudinal human immunodeficiency virus type 1 load in the italian seroconversion study: correlates and temporal trends of virus load. , 1999, The Journal of infectious diseases.

[23]  J. Margolick,et al.  Sex differences in HIV-1 viral load and progression to AIDS , 1998, The Lancet.

[24]  D. Vlahov,et al.  Direct comparison of time to AIDS and infectious disease death between HIV seroconverter injection drug users in Italy and the United States: results from the ALIVE and ISS studies. AIDS Link to Intravenous Experiences. Italian Seroconversion Study. , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[25]  K Henry,et al.  The Case for More Cautious, Patient-Focused Antiretroviral Therapy , 2000, Annals of Internal Medicine.

[26]  J. Margolick,et al.  Virologic and serologic markers of rapid progression to AIDS after HIV-1 seroconversion. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[27]  R. Chaisson,et al.  Race, sex, drug use, and progression of human immunodeficiency virus disease. , 1995, The New England journal of medicine.

[28]  M A Fischl,et al.  Antiretroviral Therapy in Adults Updated Recommendations of the International AIDS Society–USA Panel , 2000 .

[29]  J. Margolick,et al.  Quality control in the flow cytometric measurement of T-lymphocyte subsets: the multicenter AIDS cohort study experience. The Multicenter AIDS Cohort Study Group. , 1990, Clinical immunology and immunopathology.